Search results

ANSTO today welcomed a significant Federal Government funding allocation to further safeguard the production of life-saving nuclear medicines in Australia.

Detailed data on ANSTO electricity use and CO2 emissions for FY2022 - FY2023

The Japanese experience with leading-edge radiation treatment for cancer shows tremndous success

ANSTO shared expertise on next-generation reactors and nuclear power with sustainable energy experts at the Australian Academy of Science symposium in May.

Highlighting the contribution of four inspirational ANSTO leaders on International Women's Day.

An international team led by scientists at City University of Hong Kong has found flexible metal-organic framework (MOF) with one-dimensional channels that acts as a “molecular trapdoor” to selectively adsorb gases, such as carbon dioxide, in response to temperature and pressure changes.

ANSTO’s nuclear medicine processing and distribution facility assembles, loads, tests and distributes a range of nuclear medicine products, including Mo-99. The Mo-99 is dispensed into an ANSTO radiopharmaceutical Gentech® Generator where it decays to Tc-99m.

With over 70 years of nuclear expertise, ANSTO offers expert education and training programs

Lithium Australia, a company that has a close association with ANSTO’s business unit Minerals, has been awarded a US patent for its unique lithium mining technology SiLeach®.

Discover the many career opportunities in the nuclear industry on a special behind the scenes tour of ANSTO.

Imaging protocol assesses molecular mechanism of work in the treatment of deadly childhood cancer neuroblastoma.

Research will change understanding of Australian Aboriginal rock art found in rock shelters of the Kimberley and its relationship to a changing landscape

ANSTO’s Innovation Precinct welcomes NSW Government’s $12.5 commitment funding.

ANSTO has a full suite of mineralogical, chemical and hydrometallurgical facilities from laboratory through to pilot scale.

The nuclear analysis team at ANSTO recently had a significant role in the re-design and optimisation of a cold neutron source facility for the reactor, its installation and the subsequent restart after a six-month shutdown.

Developed by ANSTO’s predecessor the Australian Atomic Energy Commission (known as the AAEC) in the late 1960s, the Technetium-99m Generator revolutionised nuclear medicine imaging in Australia by enabling imaging procedures to be performed not only in major capital cities but throughout regional and rural Australia.